Deregulation of miRNAs in malignant pleural mesothelioma is associated with prognosis and suggests an alteration of cell metabolism

Authors: Chiara De Santi, Ombretta Melaiu, Alessandra Bonotti, Luciano Cascione, Gianpiero Di Leva, Rudy Foddis, Alfonso Cristaudo, Marco Lucchi, Marco Mora, Anna Truini, Andrea Tironi, Bruno Murer, Renzo Boldorini, Monica Cipollini, Federica Gemignani, Pierluigi Gasparini, Luciano Mutti, Stefano Landi

Source: Scientific Reports, Vol 7, Iss 1, Pp 1-11 (2017)

Subject Terms: Medicine, Science

File Description: electronic resource

Relation: https://doaj.org/toc/2045-2322

Access URL: https://doaj.org/article/0ce7498b7bb2420192228c3b04550780

When RON MET TAM in Mesothelioma: All Druggable for One, and One Drug for All?

Authors: Anne-Marie Baird, David Easty, Monika Jarzabek, Liam Shiels, Alex Soltermann, Sonja Klebe, Stéphane Raeppel, Lauren MacDonagh, Chengguang Wu, Kim Griggs, Michaela B. Kirschner, Bryan Stanfill, Daisuke Nonaka, Chandra M. Goparaju, Bruno Murer, Dean A. Fennell, Dearbhaile M. O'Donnell, Martin P. Barr, Luciano Mutti, Glen Reid, Stephen Finn, Sinead Cuffe, Harvey I. Pass, Isabelle Opitz, Annette T. Byrne, Kenneth J. O'Byrne, Steven G. Gray

Source: Frontiers in Endocrinology, Vol 10 (2019)

Subject Terms: Malignant Pleural Mesothelioma, RON, MET, TAM, RTK, MST1, Diseases of the endocrine glands. Clinical endocrinology, RC648-665

File Description: electronic resource

Relation: https://www.frontiersin.org/article/10.3389/fendo.2019.00089/full; https://doaj.org/toc/1664-2392

Access URL: https://doaj.org/article/567be960042e4cd789610ded3489753b

EGFR and K-ras mutations along the spectrum of pulmonary epithelial tumors of the lung and elaboration of a combined clinicopathologic and molecular scoring system to predict clinical responsiveness to EGFR inhibitors.

Authors: Giuliana Sartori, Alberto Cavazza, Alessandro Sgambato, Alessandro Marchioni, Fausto Barbieri, Lucia Longo, Mario Bavieri, Bruno Murer, Emmanuela Meschiari, Stefano Tamberi, Annamaria Cadioli, Fabrizio Luppi, Mario Migaldi, Giulio Rossi

Source: American Journal of Clinical Pathology; Apr2009, Vol. 131 Issue 4, p478-489, 12p

Subject Terms: GENETIC mutation, EPIDERMAL growth factor, LUNG tumors, EPITHELIUM, PROTEIN-tyrosine kinase inhibitors, RETROSPECTIVE studies, ADENOCARCINOMA, HEALTH & race

Prognostic significance of p16/cdkn2a loss in pleural malignant mesotheliomas.

Authors: Sanja Dacic, Hannelore Kothmaier, Stephanie Land, Yongli Shuai, Iris Halbwedl, Patrizia Morbini, Bruno Murer, Camilla Comin, Françoise Galateau-Salle, Funda Demirag, Handan Zeren, Richard Attanoos, Alan Gibbs, Philip Cagle, Helmut Popper

Source: Virchows Archiv: European Journal of Pathology; Dec2008, Vol. 453 Issue 6, p627-635, 9p

Claudin 4 identifies a wide spectrum of epithelial neoplasms and represents a very useful marker for carcinoma versus mesothelioma diagnosis in pleural and peritoneal biopsies and effusions.

Authors: Fabio Facchetti, Silvia Lonardi, Francesca Gentili, Luisa Bercich, Marcella Falchetti, Regina Tardanico, Carla Baronchelli, Laura Lucini, Alessandro Santin, Bruno Murer

Source: Virchows Archiv: European Journal of Pathology; Sep2007, Vol. 451 Issue 3, p669-680, 12p